Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
DYN shares jump 10% after launching a phase III study of z-rostudirsen in Duchenne muscular dystrophy patients amenable to exon 51 skipping.
Zacks·5h ago
More News
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA filing plans.
Zacks·5h ago
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
Atara stock soars 82% as the FDA outlines a regulatory pathway for its lead product candidate, tab-cel, reviving hopes for potential U.S. approval, after two prior CRLs.
Zacks·6h ago
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.
Zacks·7h ago
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
TG Therapeutics gains on strong Briumvi sales growth, higher 2026 revenue guidance and advancing late-stage studies in RMS.
Zacks·1d ago
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.
Zacks·1d ago
FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy
ImmunityBio's shares rise after the FDA accepts a filing to expand Anktiva's use in bladder cancer, with a decision due by January 2027.
Zacks·1d ago
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study
BioMarin shares fall after BMN 401 meets a biomarker goal but misses a key radiographic endpoint in a late-stage ENPP1 deficiency study.
Zacks·2d ago
Merck's ADC Candidate Meets Goals in Endometrial Cancer Study
MRK's investigational TROP2-directed ADC, sac-TMT, achieves key survival goals in a phase III endometrial cancer study.
Zacks·2d ago
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.